Blog
RSS FeedPosted by Michael Wonder on 29 Sep 2020
U.S. FDA approves Pfizer's Xeljanz (tofacitinib) for the treatment of active polyarticular course juvenile idiopathic arthritis
28 September 2020 - Pfizer announced today that the U.S. FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents ...
Posted by Michael Wonder on 28 Sep 2020
Orchard Therapeutics receives EMA PRIME designation for OTL-203 for the treatment of MPS-I
28 September 2020 - Orchard Therapeutics today announced that the EMA has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ...
Posted by Michael Wonder on 28 Sep 2020
Maritime union rejects claims medical supplies and food are being held up in pay dispute
29 September 2020 - There are fears container ships stuck off the Sydney coast could result in major delays to ...
Posted by Michael Wonder on 28 Sep 2020
Worst-rank score methods—a non-parametric approach to informatively missing data
28 September 2020 - A previous JAMA Guide to Statistics and Methods article briefly reviewed non-parametric statistics. ...
Posted by Michael Wonder on 28 Sep 2020
U.S. FDA approves Haegarda (C1 esterase inhibitor subcutaneous [human]) for prevention of hereditary angioedema attacks in paediatric patients
28 September 2020 - Haegarda is the first and only subcutaneous prophylactic hereditary angioedema treatment approved for children 6 years of ...
Posted by Michael Wonder on 28 Sep 2020
AbbVie receives orphan drug and fast track designations from the U.S. FDA for elezanumab, an investigational monoclonal antibody RGMa inhibitor, for the treatment of spinal cord injury
28 September 2020 - Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury. ...
Posted by Michael Wonder on 28 Sep 2020
Khondrion receives rare paediatric disease designation for sonlicromanol from US FDA
28 September 2020 - Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. ...
Posted by Michael Wonder on 28 Sep 2020
Trump seeks boost from seniors with $200 drug discount coupons
27 September 2020 - President Trump is throwing a pre-election curveball aimed at seniors with a surprise announcement on Thursday ...
Posted by Michael Wonder on 28 Sep 2020
Blueprint Medicines announces European Commission approval of Ayvakyt (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastro-intestinal stromal tumours
25 September 2020 - First highly effective treatment option approved in Europe for PDGFRA D842V mutant GIST. ...
Posted by Michael Wonder on 28 Sep 2020
FDA approves Bausch & Lomb Alaway preservative free (ketotifen fumarate 0.035% ophthalmic solution)
25 September 2020 - First OTC preservative free eye drop approved for the treatment of itchy eyes associated with allergies. ...
Posted by Michael Wonder on 27 Sep 2020
Medicine shortage fears amid MUA pay dispute
28 September 2020 - Critical medicines are blocked from entering Australia as the supply chain becomes collateral damage in a wharfie ...
Posted by Michael Wonder on 27 Sep 2020
Precision BioSciences receives fast track designation from U.S. FDA for PBCAR269A, an investigational allogeneic CAR-T therapy for relapsed/refractory multiple myeloma
9 September 2020 - Precision BioSciences today announced the U.S. FDA has granted fast track designation to PBCAR269A for the treatment ...
Posted by Michael Wonder on 26 Sep 2020
FDA grants rare paediatric disease designation to volasertib for rhabdomyosarcoma
25 September 2020 - Oncoheroes Biosciences is pleased to announce that the United States FDA has granted the designation of rare ...
Posted by Michael Wonder on 26 Sep 2020
FDA approves Kalydeco (ivacaftor) as first and only CFTR modulator to treat eligible infants with CF as early as four months of age
25 September 2020 - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before. ...
Posted by Michael Wonder on 26 Sep 2020
European Commission grants marketing authorisation for Jyseleca (filgotinib) for the treatment of adults with moderate to severe active rheumatoid arthritis
25 September 2020 - Jyseleca demonstrated durable efficacy combined with a consistent safety profile in rheumatoid arthritis through 52 weeks in ...